

Miren Ettcheto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4455335/miren-ettcheto-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64

papers

1,888

citations

22

h-index

42

g-index

74

ext. papers

2,563

ext. citations

5.7

avg, IF

4.88

L-index

#	Paper	IF	Citations
64	Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.. <i>Ageing Research Reviews</i> , 2022 , 101612	12	3
63	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function.. <i>Molecular Medicine</i> , 2022 , 28, 48	6.2	1
62	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, S91-S107	4.3	2
61	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment.. <i>International Journal of Pharmaceutics</i> , 2021 , 612, 121379	6.5	2
60	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. <i>Nutritional Neuroscience</i> , 2021 , 1-11	3.6	
59	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. <i>Pharmaceutics</i> , 2021 , 14,	5.2	6
58	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 812-839	8.3	16
57	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, S127-S139	4.3	3
56	Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment. <i>Pharmaceutics</i> , 2021 , 14,	5.2	2
55	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021 , 19, 122	9.4	12
54	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 4305	2.6	5
53	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. <i>Nanomedicine</i> , 2021 , 16, 19-35	5.6	7
52	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APP ^{swe} /PS1 ^{dE9} mice. <i>Cell and Bioscience</i> , 2021 , 11, 141	9.8	2
51	Masitinib for the treatment of Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2021 , 11, 263-276	2.8	2
50	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. <i>Toxics</i> , 2021 , 9,	4.7	2
49	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment. <i>Pharmaceutics</i> , 2021 , 14,	5.2	3
48	Lipid Nanoparticles for the Posterior Eye Segment.. <i>Pharmaceutics</i> , 2021 , 14,	6.4	10

47	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. <i>Journal of Nanobiotechnology</i> , 2020 , 18, 156	9.4	17
46	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. <i>Nanomedicine</i> , 2020 , 15, 1239-1261	5.6	35
45	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Discovery</i> , 2020 , 15, 993-1004	6.2	2
44	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. <i>Nanomaterials</i> , 2020 , 10,	5.4	355
43	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. <i>Nanomaterials</i> , 2020 , 10,	5.4	22
42	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1286-1299	3.3	6
41	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. <i>Molecular Neurobiology</i> , 2020 , 57, 1814-1827	6.2	28
40	Involvement of JNK1 in Neuronal Polarization During Brain Development. <i>Cells</i> , 2020 , 9,	7.9	3
39	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 236	5.3	25
38	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. <i>Pharmaceutics</i> , 2019 , 11,	6.4	68
37	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. <i>Molecular Neurobiology</i> , 2019 , 56, 5856-5865	6.2	13
36	Current Applications of Nanoemulsions in Cancer Therapeutics. <i>Nanomaterials</i> , 2019 , 9,	5.4	72
35	A metabolic perspective of late onset Alzheimer's disease. <i>Pharmacological Research</i> , 2019 , 145, 104255	10.2	12
34	Isoform-selective as opposed to complete depletion of fibroblast growth factor 2 (FGF-2) has no major impact on survival and gene expression in SOD1 amyotrophic lateral sclerosis mice. <i>European Journal of Neuroscience</i> , 2019 , 50, 3028-3045	3.5	1
33	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. <i>Biomedicine and Pharmacotherapy</i> , 2019 , 113, 108661	7.5	38
32	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. <i>Journal of Controlled Release</i> , 2019 , 301, 62-75	11.7	122
31	Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model. <i>Journal of Neurochemistry</i> , 2019 , 149, 255-268	6	6
30	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 344	5.3	14

29	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. <i>Neural Regeneration Research</i> , 2019 , 14, 1721-1725	4.5	2
28	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	11
27	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1723-1733	5.5	7
26	Characterizing the multiple roles of FGF-2 in SOD1 ALS mice in vivo and in vitro. <i>Journal of Cellular Physiology</i> , 2019 , 234, 7395-7410	7	8
25	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018 , 14, 1073-1085	6	37
24	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018 , 55, 7327-7339	6.2	18
23	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1223-1240	4.3	95
22	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. <i>Journal of Nanobiotechnology</i> , 2018 , 16, 32	9.4	97
21	Review of the advances in treatment for Alzheimer disease: strategies for combating β amyloid protein. <i>Neurologia (English Edition)</i> , 2018 , 33, 47-58	0.4	12
20	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018 , 55, 4885-4895	6.2	16
19	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. <i>Pharmaceuticals</i> , 2018 , 11,	5.2	32
18	Experimental Models for Aging and their Potential for Novel Drug Discovery. <i>Current Neuropharmacology</i> , 2018 , 16, 1466-1483	7.6	19
17	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO1-1-32	0	
16	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. <i>Neuropharmacology</i> , 2018 , 131, 440-452	5.5	16
15	Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. <i>Small</i> , 2018 , 14, 1701808	11	58
14	The Ethyl Acetate Extract of Leaves of <i>Ugni molinae</i> Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1175-1191	4.3	7
13	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. <i>Redox Biology</i> , 2017 , 13, 345-352	11.3	24
12	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. <i>Pharmacological Reports</i> , 2017 , 69, 409-418	3.9	12

11	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APP ^{swe} /PS1 ^{dE9} . <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 1171-1182	6	45
10	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. <i>Frontiers in Bioscience - Landmark</i> , 2017 , 22, 795-814	2.8	15
9	Long-term exposition to a high fat diet favors the appearance of β-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2017 , 162, 38-45	5.6	61
8	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016 , 53, 6183-6193	6.2	16
7	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. <i>Neural Plasticity</i> , 2016 , 2016, 8501693	3.3	153
6	Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 233-51	4.3	32
5	PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016 , 145, 241-250	6	82
4	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. <i>Molecular Neurobiology</i> , 2015 , 52, 120-9	6.2	5
3	The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. <i>Life Sciences</i> , 2015 , 140, 19-28	6.8	24
2	Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLR knockout and APP ^{swe} /PS1 ^{dE9} mice. <i>Experimental Gerontology</i> , 2015 , 65, 69-78	4.5	15
1	Masitinib for the treatment of mild to moderate Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 587-96	4.3	42